MedTrace Logo

Anti-Angiogenic Preeclampsia Milieu Impairs Infant Lung and Vascular Development

NCT02639676 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 292

Last updated 2022-02-24

No results posted yet for this study

Summary

Pregnant mothers who develop high blood pressure and other vascular problems (preeclampsia) deliver babies with increased neonatal health problems, which include lung disease and vascular complications, later in life. Investigators will evaluate whether infants of mothers with preeclampsia have evidence for impaired development of the lungs and blood vessels.

Conditions

Interventions

OTHER

Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections

Sponsors & Collaborators

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • National Institutes of Health (NIH)

    collaborator NIH

  • Indiana University

    lead OTHER

Principal Investigators

  • Robert S Tepper, MD, PhD · Indiana University

Eligibility

Min Age
26 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-11
Primary Completion
2020-11-17
Completion
2020-11-17

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02639676 on ClinicalTrials.gov